• Pooja Agarwal
  • J. K. Badjatya


A Drug Master File or DMF is a reference source that provides drug evaluator’s confidential information not available to drug product manufacturer about the specific process and components used in the manufacturing, processing and packaging of a drug meant for Human/Animal use. The submission of a DMF is not required by law or FDA regulation. A DMF is submitted solely at the discretion of the holder. The information contained in the DMF may be used to support an Investigational New Drug Application (IND), a New Drug Application (NDA), an Abbreviated New Drug Application (ANDA), another DMF, or amendments and supplements to any of these.

Keywords: DMF, ICH CTD, AP. RP, FDA, QOS, CMC.


Download data is not yet available.


1. Guideline for Drug Master Files [Internet]. CDER, FDA; 2005 Mar[cited 2015 Nov 15]. Available from:
2. Guidelines for drug master files, United States, Food and Drug Administration [Internet]. USFDA; 2011 Nov 14 [cited 2015 Nov 09]. Available from:
3. Guidelines for drug master files, CDER FDA [Internet]. FDA; 2015 [cited 2015 Nov 12].
Available from:
4. Forms and Submission requirements [Internet]. FDA; 2015 Nov [cited 2015 Nov 08]. Available from: Submission
5. Requirements/Drug Master Files DMF’s [Internet]. FDA; 2013 Feb 11 [cited 2015 Nov 08].
Available from:
6. Classifying resubmission of original NDAs, BLAs, and efficacy supplements in response to complete response letters. [Internet]. [Cited on 4 April 2013].
[Internet] FDA; 1998 May 1 [cited 2015 Nov 15]. Available from:
7. Compliance Regulatory [Internet]. FDA; 2013 June [cited 2015 Nov 12]. Available from:
8. DMF fees in USA [Internet] Washington, DC: GPO; 2013 [cited 2015 Sept 03]. Available from: 02/pdf/ 2013 -18625.pdf.
9. ASMF filling fees [Internet]. MHRA; 2014[cited 2015 Nov 02]. Available from:
10. Canada DMF fees [Internet]. Health Canada; 2013[cited 2015 Nov 03]. Available from:
1410 Views | 3971 Downloads
How to Cite
Agarwal, P., and J. K. Badjatya. “DMF FILING IN US, EUROPE AND CANADA”. International Journal of Drug Regulatory Affairs, Vol. 3, no. 4, Feb. 2018, pp. 9-17, doi:10.22270/ijdra.v3i4.172.

Most read articles by the same author(s)